Cooper Companies (COO) stock plummeted 5.39% in the intraday trading session on Friday, following mixed first-quarter results that prompted several analysts to lower their price targets and ratings on the medical device maker.
After reporting a revenue shortfall but an earnings beat for Q1 2025, Cooper Companies faced a wave of price target cuts from Wall Street firms. Citi lowered its target to $110 from $115 while maintaining a Buy rating, while Baird cut its target to $107 from $117 and reiterated an Outperform rating.
Morgan Stanley analysts maintained a Hold rating on the stock, noting challenges and opportunities ahead for the company. JPMorgan also trimmed its price target to $110 from $120 but kept an Overweight rating, while Needham reiterated a Hold stance, citing Cooper's mixed Q1 performance.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。